title: Thiopurines and myeloid disorders: is more caution needed when treating inflammatory bowel disease patients?
abstract: Thiopurines remain the backbone therapy of inflammatory bowel diseases (IBD). However, these drugs have potential mutagenic and carcinogenic effects, especially when prescribed for a long time. In addition to the increased risk of lymphoma and non-melanoma skin cancer, recent data suggest that risk of myeloid disorder is increased in IBD patients with past exposure to thiopurines. Even if individual risk is low, practitioners who take care of IBD patients should be aware of this potential complication of thiopurines treatment.
authors.affiliation: Inserm, U954 and Department of Hepato-Gastroenterology, University Hospital of Nancy, Université de Lorraine, Allée du Morvan, 54511 Vandoeuvre-lès-Nancy, France.
authors.forename: Anthony
authors.initials: A
authors.lastname: Lopez
authors.forename: Laurent
authors.initials: L
authors.lastname: Beaugerie
authors.forename: Laurent
authors.initials: L
authors.lastname: Peyrin-Biroulet
mesh_terms: D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D007938:Leukemia / Q000139:chemically induced*; D009190:Myelodysplastic Syndromes / Q000139:chemically induced*; D011687:Purines / Q000009:adverse effects*
chemical_list: D000893:Anti-Inflammatory Agents; D011687:Purines
keywords: acute myeloid leukemia; inflammatory bowel diseases; myelodysplastic syndrome; purines analogs